{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T10:15:21Z","timestamp":1758190521989,"version":"3.44.0"},"reference-count":130,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Scientific research has significantly propelled advancements in healthcare. One notable application is precision medicine, which seeks to analyze and comprehend disease pathology to offer personalized medical treatments to patients. Targeted oncology, a branch of precision medicine, focuses on identifying and targeting specific molecules that regulate cancer cells, thereby minimizing harm to healthy cells. Different types of targeted therapy against cancer include monoclonal antibodies and small molecules. This manuscript intends to provide an overview of the influence of these targeted oncology and non-oncology therapies on hearing. Furthermore, side effects including immune-related adverse events will be reviewed as potential causes of hearing deterioration in this patient population.<\/jats:p>","DOI":"10.3389\/fphar.2025.1620679","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T05:45:42Z","timestamp":1758087942000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The influence of targeted therapies in the inner ear"],"prefix":"10.3389","volume":"16","author":[{"given":"Tony","family":"Bonilla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jake","family":"DiFatta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esperanza","family":"Bas Infante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Goncalves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12879-021-06956-1","article-title":"Chronic aseptic meningitis caused by enterovirus in a humorally immunosuppressed adult patient presenting with sensorineural hearing loss: a case report","volume":"22","author":"Anderson","year":"2022","journal-title":"BMC Infect. Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"459","DOI":"10.4103\/0019-509X.200675","article-title":"Sensorineural deafness: an uncommon irreversible adverse effect of bortezomib","volume":"53","author":"Anoop","year":"2016","journal-title":"Indian J. Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1002\/lary.31763","article-title":"The impact of monoclonal antibody usage on hearing outcomes: a systematic review","volume":"135","author":"Arya","year":"2025","journal-title":"Laryngoscope"},{"key":"B4","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.leukres.2007.11.039","article-title":"Irreversible sensorineural hearing loss due to imatinib","volume":"32","author":"Attili","year":"2008","journal-title":"Leuk. Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.3389\/fphar.2019.01161","article-title":"Ototoxic adverse drug reactions: a disproportionality analysis using the Italian spontaneous reporting database","volume":"10","author":"Barbieri","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.mehy.2015.06.009","article-title":"Audiovestibular disorders as autoimmune reaction in patients with melanoma","volume":"85","author":"Barozzi","year":"2015","journal-title":"Med. Hypotheses"},{"key":"B7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/IOP.0000000000001995","article-title":"Teprotumumab and hearing loss: case series and proposal for audiologic monitoring","volume":"38","author":"Belinsky","year":"2022","journal-title":"Ophthalmic plastic Reconstr. Surg."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1634\/theoncologist.2012-0044","article-title":"FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors","volume":"17","author":"Blumenthal","year":"2012","journal-title":"Oncol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1007\/s11606-022-07735-7","article-title":"Model-projected cost-effectiveness of adult hearing screening in the USA","volume":"38","author":"Borre","year":"2023","journal-title":"J. Gen. Intern. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1080\/14737175.2022.2128769","article-title":"Considering hearing loss as a modifiable risk factor for dementia","volume":"22","author":"Brewster","year":"2022","journal-title":"Expert Rev. Neurother."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.24711","article-title":"Granulomatosis with polyangiitis presenting as complete hearing loss","author":"Busch","year":"2022","journal-title":"Cureus"},{"key":"B11","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1177\/0003489420938827","article-title":"Cochlear implantation as a treatment for sudden autoimmune sensorineural hearing loss in a patient affected by eosinophilic granulomatosis with polyangiitis: a case report and A review of literature","volume":"130","author":"Cacco","year":"2021","journal-title":"Ann. Otology, Rhinology and Laryngology"},{"key":"B121","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s40264-017-0629-8","article-title":"Drug-induced ototoxicity: diagnosis and monitoring","volume":"41","author":"Campbell","year":"2018","journal-title":"Drug Saf."},{"key":"B12","article-title":"Erlotinib","author":"Carter","year":"2025"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e20048","DOI":"10.1097\/MD.0000000000020048","article-title":"A case report of Hodgkin lymphoma in a patient treated with ustekinumab for psoriasis","volume":"99","author":"Charakopoulos","year":"2020","journal-title":"Medicine"},{"key":"B14","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/978-981-96-0301-5_12","article-title":"Small molecule inhibitors: precision tools targeting oncogenic pathways for therapeutic intervention in cancer","volume-title":"Small molecules for cancer treatment","author":"Chattopadhyay","year":"2024"},{"key":"B15","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/j.1365-2141.2012.09202.x","article-title":"Therapy-related classical Hodgkin lymphoma after a primary haematological malignancy: a report on 13 cases","volume":"158","author":"Cheminant","year":"2012","journal-title":"Br. J. Haematol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1097\/WAD.0000000000000325","article-title":"Age-related hearing loss and dementia","volume":"33","author":"Chern","year":"2019","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"B17","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1080\/02841860701558823","article-title":"Deafness associated with the use of Bortezomib in multiple myeloma","volume":"47","author":"Chim","year":"2008","journal-title":"Acta Oncol. Stockh. Swed."},{"key":"B18","doi-asserted-by":"publisher","first-page":"E35-E42","DOI":"10.1002\/hed.26455","article-title":"Recurrent audiovestibular dysfunction and associated neurological immune\u2010related adverse events in a melanoma patient treated with nivolumab and ipilimumab","volume":"42","author":"Choi","year":"2020","journal-title":"Head. Neck"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e248335","DOI":"10.1136\/bcr-2021-248335","article-title":"Teprotumumab\u2010associated chronic hearing loss screening and proposed treatments","volume":"15","author":"Chow","year":"2022","journal-title":"BMJ Case Rep."},{"key":"B20","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1634\/theoncologist.8-4-303","article-title":"FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets","volume":"8","author":"Cohen","year":"2003","journal-title":"Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3899\/jrheum.10593","article-title":"Use of adalimumab in treatment of autoimmune sensorineural hearing loss: a word of caution","volume":"38","author":"Conway","year":"2011","journal-title":"J. Rheumatology"},{"key":"B119","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1172\/JCI96798","article-title":"Early B cell changes predict autoimmunity following combination immune checkpoint blockade","volume":"128","author":"Das","year":"2018","journal-title":"J. Clin. Invest."},{"key":"B23","doi-asserted-by":"publisher","first-page":"102175","DOI":"10.1016\/j.rmcr.2025.102175","article-title":"Solitary metastasis in the internal auditory canal from non-small cell lung carcinoma: a case report","volume":"53","author":"De Boos","year":"2025","journal-title":"Respir. Med. Case Rep."},{"key":"B24","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1007\/s00415-019-09587-4","article-title":"Susac's syndrome as an immune\u2010related adverse event after pembrolizumab: a case report","volume":"267","author":"De Groot","year":"2020","journal-title":"J. Neurol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/MPH.0b013e31815d1d83","article-title":"Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens","volume":"30","author":"Dean","year":"2008","journal-title":"J. Pediatr. Hematology\/oncology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1007\/s10637-016-0378-z","article-title":"Sunitinib-induced sudden hearing loss","volume":"34","author":"Dekeister","year":"2016","journal-title":"Investig. New Drugs"},{"key":"B27","doi-asserted-by":"publisher","first-page":"832","DOI":"10.18553\/jmcp.2020.26.7.832","article-title":"Indications for rituximab use in an integrated health care delivery System","volume":"26","author":"Delate","year":"2020","journal-title":"J. Manag. Care and Specialty Pharm."},{"key":"B28","doi-asserted-by":"publisher","first-page":"102203","DOI":"10.1016\/j.canep.2022.102203","article-title":"Global burden of ototoxic hearing loss associated with platinum-based cancer treatment: a systematic review and meta-analysis","volume":"79","author":"Dillard","year":"2022","journal-title":"Cancer Epidemiol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.1097\/MAO.0000000000003428","article-title":"Sensorineural hearing loss after teprotumumab therapy for thyroid eye disease: a case report","volume":"43","author":"Ding","year":"2022","journal-title":"Otol. Neurotol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1210\/clinem\/dgad637","article-title":"Efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity","volume":"109","author":"Douglas","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e674","DOI":"10.1097\/MAO.0000000000002332","article-title":"Sensorineural hearing loss after adoptive cell immunotherapy for Melanoma using MART-1 specific T cells: a case report and its pathophysiology","volume":"40","author":"Duinkerken","year":"2019","journal-title":"Otology and Neurotol. official Publ. Am. Otological Soc. Am. Neurotol. Soc. Eur. Acad. Otology Neurotol."},{"key":"B122","article-title":"Position statement and clinical practice guidelines: otoxocicity monitoring","author":"Durrant","year":"2009","journal-title":"AAA"},{"key":"B32","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/sj.leu.2403723","article-title":"Severe irreversible bilateral hearing loss after bortezomib (VELCADE) therapy in a multiple myeloma (MM) patient","volume":"19","author":"Engelhardt","year":"2005","journal-title":"Leukemia"},{"key":"B33","doi-asserted-by":"publisher","first-page":"207","DOI":"10.5152\/iao.2015.912","article-title":"Evaluation of Lapatinib and trastuzumab for ototoxic effects","volume":"11","author":"Eryilmaz","year":"2016","journal-title":"J. Int. Adv. Otology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/fcp.12533","article-title":"Drug\u2010induced hearing loss: a case\/non\u2010case study in the French pharmacovigilance database","volume":"34","author":"Favreli\u00e8re","year":"2020","journal-title":"Fundam. and Clin. Pharmacol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1159\/000539453","article-title":"Hearing loss in a patient with Waldenstrom macroglobulinemia receiving bortezomib","volume":"17","author":"Fitzsimons","year":"2024","journal-title":"Case Rep. Oncol."},{"key":"B36","article-title":"Imatinib. 2023","volume-title":"Treasure Island, FL","author":"Flynn","year":"2025"},{"key":"B37","doi-asserted-by":"publisher","first-page":"439","DOI":"10.2217\/imt-2019-0206","article-title":"Concurrent Vogt\u2010Koyanagi\u2010Harada disease and impressive response to immune checkpoint blockade in metastatic melanoma","volume":"12","author":"Gambichler","year":"2020","journal-title":"Immunotherapy"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/genes12101553","article-title":"Insulin-like growth factor 1 signaling in Mammalian hearing","volume":"12","author":"Garc\u00eda-Mato","year":"2021","journal-title":"Genes"},{"key":"B39","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations","volume":"6","author":"Gong","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1158\/1078-0432.CCR-06-2328","article-title":"Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma","volume":"13","author":"Goodman","year":"2007","journal-title":"Clin. cancer Res. official J. Am. Assoc. Cancer Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s40265-015-0533-4","article-title":"Osimertinib: first global approval","volume":"76","author":"Greig","year":"2016","journal-title":"Drugs"},{"key":"B42","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/hon.2365","article-title":"Enteroviral infection in patients treated with rituximab for non\u2010Hodgkin lymphoma: a case series and review of the literature","volume":"35","author":"Grisariu","year":"2017","journal-title":"Hematol. Oncol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/01.mph.0000199586.98926.8e","article-title":"Low incidence of ototoxicity with continuous infusion of cisplatin in the treatment of pediatric germ cell tumors","volume":"28","author":"Gupta","year":"2006","journal-title":"J. Pediatr. Hematology\/oncology"},{"key":"B44","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s12288-015-0612-4","article-title":"Audio vestibular status in CML patients on imatinib mesylate with review of literature","volume":"33","author":"Gupta","year":"2017","journal-title":"Indian J. Hematol. Blood Transfus."},{"key":"B45","article-title":"Rituximab. 2024","volume-title":"Treasure Island, FL","author":"Hanif","year":"2025"},{"key":"B46","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1177\/000348949710600804","article-title":"Reversible sensorineural hearing loss after renal transplant immunosuppression with OKT3 (muromonab\u2010CD3)","volume":"106","author":"Hartnick","year":"1997","journal-title":"Ann. Otol. Rhinol. Laryngol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.nmd.2015.04.004","article-title":"Clinical, neuropathological and radiological evidence for a rare complication of rituximab therapy","volume":"25","author":"Healy","year":"2015","journal-title":"Neuromuscul. Disord."},{"key":"B48","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1177\/00034894211042740","article-title":"Ototoxicity and teprotumumab","volume":"131","author":"Highland","year":"2022","journal-title":"Ann. Otol. Rhinol. Laryngol."},{"key":"B49","article-title":"A case of pembrolizumab induced autoimmune sensorineural hearing loss","volume":"8","author":"Hobelmann","year":"2019","journal-title":"J. Otol. Rhinol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"100047","DOI":"10.1016\/j.ajoint.2024.100047","article-title":"Teprotumumab-associated aural fullness and ageusia: a case report of persistent complications following thyroid eye disease treatment","volume":"1","author":"Hsiou","year":"2024","journal-title":"AJO Int."},{"key":"B124","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1177\/01640275211008583","article-title":"Cost-effectiveness of hearing screening in older adults: a scoping review","volume":"44","author":"Hsu","year":"2022","journal-title":"Res. Aging"},{"key":"B51","doi-asserted-by":"publisher","first-page":"e566","DOI":"10.1097\/MAO.0000000000004260","article-title":"A biologic with otologic consequences: analysis of hearing loss and teprotumumab using the FDA adverse event reporting System","volume":"45","author":"Huynh","year":"2024","journal-title":"Otology and Neurotol. official Publ. Am. Otological Soc. Am. Neurotol. Soc. Eur. Acad. Otology Neurotol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/S2213-8587(21)00056-5","article-title":"Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off\u2010treatment follow\u2010up results from two randomised, double\u2010masked, placebo\u2010controlled, multicentre trials","volume":"9","author":"Kahaly","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1634\/theoncologist.8-6-508","article-title":"Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy","volume":"8","author":"Kane","year":"2003","journal-title":"Oncol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s40425-018-0463-2","article-title":"Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations","volume":"6","author":"Karzai","year":"2018","journal-title":"J. Immunother. cancer"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1002\/ohn.174","article-title":"Prospective assessment of otologic adverse events due to teprotumumab: preliminary results","volume":"168","author":"Kay\u2010Rivest","year":"2023","journal-title":"Otolaryngol. Head. Neck Surg."},{"key":"B56","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ophtha.2023.08.001","article-title":"Frequency and patterns of hearing dysfunction in patients treated with teprotumumab","volume":"131","author":"Keen","year":"2024","journal-title":"Ophthalmology"},{"key":"B57","doi-asserted-by":"publisher","first-page":"4597","DOI":"10.62347\/OKGQ4382","article-title":"Hearing loss during chemotherapy: prevalence, mechanisms, and protection","volume":"14","author":"Kessler","year":"2024","journal-title":"Am. J. Cancer Res."},{"key":"B58","doi-asserted-by":"publisher","first-page":"8588","DOI":"10.1200\/JCO.2004.00.5355","article-title":"Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development","volume":"23","author":"Knight","year":"2005","journal-title":"J. Clin. Oncol. official J. Am. Soc. Clin. Oncol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1044\/leader.FTR1.10072005.1","article-title":"Ototoxicity: early detection and monitoring","volume":"10","author":"Konrad-Martin","year":"2005","journal-title":"ASHA Lead."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1080\/02841860802213328","article-title":"Irreversible ototoxicity associated with the use of erlotinib in a patient with pancreatic cancer","volume":"47","author":"Koutras","year":"2008","journal-title":"Acta Oncol. Stockh. Swed."},{"key":"B61","doi-asserted-by":"publisher","first-page":"e6057","DOI":"10.7759\/cureus.6057","article-title":"Investigation of the ototoxic effect of pembrolizumab using a rat model","volume":"11","author":"Kuzucu","year":"2019","journal-title":"Cureus"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1002\/cncr.29779","article-title":"Ototoxicity and cancer therapy","volume":"122","author":"Landier","year":"2016","journal-title":"Cancer"},{"key":"B63","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1200\/JCO.2013.51.2038","article-title":"Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales--a report from the Children\u2019s Oncology Group","volume":"32","author":"Landier","year":"2014","journal-title":"J. Clin. Oncol. official J. Am. Soc. Clin. Oncol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejca.2019.05.022","article-title":"Cochleovestibular toxicity induced by immune checkpoint inhibition: a case series","volume":"117","author":"Lemasson","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"B65","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/pbc.21875","article-title":"Ototoxicity in children treated for osteosarcoma","volume":"52","author":"Lewis","year":"2009","journal-title":"Pediatr. Blood and Cancer"},{"key":"B66","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12943-024-02072-1","article-title":"Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directions","volume":"23","author":"Li","year":"2024","journal-title":"Mol. Cancer"},{"key":"B67","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s43163-022-00250-w","article-title":"Osimertinib-induced hearing loss: an uncommon aftereffect of a novel drug\u2014a case report","volume":"38","author":"Lim","year":"2022","journal-title":"Egypt. J. Otolaryngology"},{"key":"B68","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1177\/0194599811415008","article-title":"Sensorineural hearing loss following imatinib (Gleevec) administration","volume":"146","author":"Lin","year":"2012","journal-title":"Otolaryngol. Head. Neck Surg."},{"key":"B200","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1055\/s-0039-1684042","article-title":"Monitoring protocols for Cochlear toxicity","volume":"40","author":"Lord","year":"2019","journal-title":"Seminars in hearing"},{"key":"B69","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1159\/000529422","article-title":"Oral corticosteroids for teprotumumab\u2010related hearing loss: a case report","volume":"14","author":"Lu","year":"2023","journal-title":"Case Rep. Ophthalmol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2165\/00003495-200262010-00008","article-title":"Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2","volume":"62","author":"McKeage","year":"2002","journal-title":"Drugs"},{"key":"B71","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1097\/IOP.0000000000002564","article-title":"Teprotumumab for the treatment of recalcitrant thyroid eye disease","volume":"40","author":"Men","year":"2024","journal-title":"Ophthal Plast. Reconstr. Surg."},{"key":"B72","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1097\/01.cad.0000361534.44052.c5","article-title":"Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib","volume":"21","author":"Mena","year":"2010","journal-title":"Anti-cancer drugs"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1097\/OPX.0000000000001798","article-title":"Case report: ipilimumab\u2010induced multisystem autoimmune\u2010like toxicities suggestive of vogt-koyanagi-harada\u2010like syndrome","volume":"98","author":"Monferrer\u2010Adsuara","year":"2021","journal-title":"Optom. Vis. Sci."},{"key":"B123","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1044\/2023_AJA-22-00157","article-title":"Is methotrexate ototoxic? investigating the ototoxic late effects of pediatric cancer treatment","volume":"32","author":"Moore","year":"2023","journal-title":"Am. J. Audiol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1634\/theoncologist.2016-0197","article-title":"Sunitinib: ten years of successful clinical use and Study in advanced renal cell carcinoma","volume":"22","author":"Motzer","year":"2017","journal-title":"Oncol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"2473974X18818791","DOI":"10.1177\/2473974X18818791","article-title":"Granulomatosis with polyangiitis presenting with bilateral hearing loss and facial paresis","volume":"3","author":"Mur","year":"2019","journal-title":"OTO Open"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2011.00011","article-title":"The role of insulin-like growth factor-I in the physiopathology of hearing","volume":"4","author":"Murrilo-Cuesta","year":"2011","journal-title":"Front. Mol. Neurosci."},{"key":"B76","doi-asserted-by":"publisher","first-page":"9565205","DOI":"10.1155\/2023\/9565205","article-title":"Outcome of nivolumab\u2010induced Vogt\u2010Koyanagi\u2010Harada disease\u2010like uveitis in a patient managed without intravenous methylprednisolone therapy","volume":"2023","author":"Nagai","year":"2023","journal-title":"Case Rep. Ophthalmol. Med."},{"key":"B77","doi-asserted-by":"publisher","first-page":"2473974X221097097","DOI":"10.1177\/2473974X221097097","article-title":"Audiologic demonstration of ototoxicity from teprotumumab treatment in a patient with thyroid eye disease","volume":"6","author":"Najjar","year":"2022","journal-title":"OTO Open"},{"key":"B78","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1177\/01945998221094457","article-title":"Ototoxicity review: a growing number of Non\u2013Platinum\u2010Based chemo\u2010 and immunotherapies","volume":"168","author":"Naples","year":"2023","journal-title":"Otolaryngology\u2013Head Neck Surg."},{"key":"B126","first-page":"153","article-title":"Psychometric adequacy of the Tinnitus Handicap Inventory (THI) for evaluating treatment outcome","volume":"9","author":"Newman","year":"1998","journal-title":"J. Am. Acad. Audiol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3892\/ol.2012.997","article-title":"Prospective evaluation of cisplatin- and carboplatin-mediated ototoxicity in paediatric and adult soft tissue and osteosarcoma patients","volume":"5","author":"Nitz","year":"2013","journal-title":"Oncol. Lett."},{"key":"B80","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/cei.13602","article-title":"Long-term exposure to monoclonal anti-TNF is associated with an increased risk of lymphoma in BAFF-transgenic mice","volume":"205","author":"Nocturne","year":"2021","journal-title":"Clin. Exp. Immunol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"18104","DOI":"10.1523\/JNEUROSCI.3619-11.2011","article-title":"Insulin-like growth factor signaling regulates the timing of sensory cell differentiation in the mouse cochlea","volume":"31","author":"Okano","year":"2011","journal-title":"J. Neurosci."},{"key":"B81","doi-asserted-by":"publisher","first-page":"2","DOI":"10.36401\/JIPO-21-17","article-title":"Audiovestibular toxicity secondary to immunotherapy: case series and literature review","volume":"5","author":"Page","year":"2022","journal-title":"J. Immunother. Precis. Oncol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"e101","DOI":"10.1097\/IOP.0000000000002355","article-title":"Reduction of teprotumumab\u2010induced hearing loss with comparable efficacy using half\u2010dose therapy","volume":"39","author":"Phansalkar","year":"2023","journal-title":"Ophthal Plast. Reconstr. Surg."},{"key":"B83","first-page":"135","article-title":"Velcade (Bortezomib) receives 2 new FDA indications: for retreatment of patients with multiple myeloma and for first-line treatment of patients with mantle-cell lymphoma","volume":"8","author":"Raedler","year":"2015","journal-title":"Am. health and drug benefits"},{"key":"B84","doi-asserted-by":"publisher","first-page":"omaa077","DOI":"10.1093\/omcr\/omaa077","article-title":"Unilateral autoimmune inner ear disease in a patient with lung cancer treated with nivolumab","volume":"2020","author":"Rajapakse","year":"2020","journal-title":"Oxf Med. Case Rep."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1186\/s10194-021-01330-7","article-title":"Calcitonin gene related peptide in migraine: current therapeutics, future implications and potential off-target effects","volume":"92","author":"Ray","year":"2021","journal-title":"J. Neurology, Neurosurg. and Psychiatry"},{"key":"B86","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1097\/IOP.0000000000002078","article-title":"Rifle blast exacerbating hearing loss in a patient treated with teprotumumab for thyroid eye disease","volume":"38","author":"Reed","year":"2022","journal-title":"Ophthal Plast. Reconstr. Surg."},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001675","article-title":"Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma","volume":"8","author":"Rosner","year":"2020","journal-title":"J. Immunother. cancer"},{"key":"B128","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/sj.ki.5002434","article-title":"Ototoxicity","volume":"72","author":"Ryback","year":"2007","journal-title":"Kidney Int."},{"key":"B88","first-page":"183","article-title":"Sensorineural hearing loss in ankylosing spondylitis treated with TNF blockers","volume":"6","author":"Savastano","year":"2010","journal-title":"B\u2010ENT"},{"key":"B89","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1200\/JCO.1989.7.6.754","article-title":"Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation","volume":"7","author":"Schell","year":"1989","journal-title":"J. Clin. Oncol. official J. Am. Soc. Clin. Oncol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1080\/14670100.2023.2193918","article-title":"Bilateral cochlear implantation after immunotherapy-related profound hearing loss: a case report","volume":"24","author":"Schlacter","year":"2023","journal-title":"Cochlear implants Int."},{"key":"B91","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1177\/0194599812448356","article-title":"Audiovestibular dysfunction associated with adoptive cell immunotherapy for melanoma","volume":"147","author":"Seaman","year":"2012","journal-title":"Otolaryngology--head neck Surg. official J. Am. Acad. Otolaryngology-Head Neck Surg."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajo.2022.02.015","article-title":"Hearing dysfunction after treatment with teprotumumab for thyroid eye disease","volume":"240","author":"Sears","year":"2022","journal-title":"Am. J. Ophthalmol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.ophtha.2023.10.018","article-title":"Teprotumumab\u2010related adverse events in thyroid eye disease: a multicenter study","volume":"131","author":"Shah","year":"2024","journal-title":"Ophthalmology"},{"key":"B94","doi-asserted-by":"publisher","first-page":"595","DOI":"10.21037\/atm.2019.05.58","article-title":"Immunotherapy and targeted therapy-the new roadmap in cancer treatment","volume":"7","author":"Shahid","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-025-02479-y","article-title":"Echovirus serotype 11 induced sepsis in a young female patient with multiple sclerosis treated with anti-CD20 monoclonal antibody ocrelizumab","author":"Starosta","year":"2025","journal-title":"Infection"},{"key":"B96","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/CJI.0000000000000367","article-title":"Sudden otovestibular dysfunction in 3 metastatic melanoma patients treated with immune checkpoint inhibitors","volume":"44","author":"St\u00fcrmer","year":"2021","journal-title":"J. Immunother."},{"key":"B97","doi-asserted-by":"publisher","first-page":"145561320940847","DOI":"10.1177\/0145561320940847","article-title":"Bilateral sensorineural hearing loss associated with nivolumab therapy for stage IV malignant melanoma","volume":"100","author":"Tampio","year":"2021","journal-title":"Ear Nose Throat J."},{"key":"B98","doi-asserted-by":"publisher","first-page":"582","DOI":"10.6004\/jnccn.2024.0057","article-title":"NCCN guidelines\u00ae insights: management of immunotherapy-related toxicities, version 2.2024","volume":"22","author":"Thompson","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"B99","doi-asserted-by":"publisher","first-page":"871","DOI":"10.2165\/00003495-198937060-00004","article-title":"Muromonab CD3. A review of its pharmacology and therapeutic potential","volume":"37","author":"Todd","year":"1989","journal-title":"Drugs"},{"key":"B100","doi-asserted-by":"publisher","first-page":"76S-91S","DOI":"10.1097\/AUD.0000000000000219","article-title":"Language outcomes in young children with mild to severe hearing loss","volume":"36","author":"Tomblin","year":"2015","journal-title":"Ear Hear."},{"key":"B101","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s00296-007-0373-y","article-title":"The use of TNF\u2010alpha blockers in Cogan's syndrome","volume":"27","author":"Touma","year":"2007","journal-title":"Rheumatol. Int."},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju044","article-title":"Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics","volume":"106","author":"Travis","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"B103","doi-asserted-by":"publisher","first-page":"e241203","DOI":"10.1136\/bcr-2020-241203","article-title":"Denosumab and bisphosphonate associated bilateral osteonecrosis of the external auditory canal","volume":"14","author":"True","year":"2021","journal-title":"BMJ Case Rep."},{"key":"B104","doi-asserted-by":"publisher","first-page":"102019","DOI":"10.1016\/j.ctrv.2020.102019","article-title":"Review of precision cancer medicine: evolution of the treatment paradigm","volume":"86","author":"Tsimberidou","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"B129","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adk2299","article-title":"In silico transcriptome screens identify epidermal growth factor receptor inhibitors as therapeutics for noise-induced hearing loss","volume":"10","author":"Vijayakumar","year":"2024","journal-title":"Sci. Adv."},{"key":"B105","doi-asserted-by":"publisher","first-page":"e356","DOI":"10.1200\/JCO.2011.41.4359","article-title":"Anti\u2010cytotoxic T\u2010cell lymphocyte antigen\u20104\u2010induced regression of spinal cord metastases in association with renal failure, atypical pneumonia, vision loss, and hearing loss","volume":"30","author":"Voskens","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"e848","DOI":"10.7759\/cureus.848","article-title":"Imatinib-induced ototoxicity in a patient with gastrointestinal stromal tumor (GIST)","volume":"8","author":"Wasif","year":"2016","journal-title":"Cureus"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov."},{"key":"B108","first-page":"1","article-title":"Ototoxicity in immune checkpoint inhibitors therapy","volume":"78","author":"Wierzbicka","year":"2024","journal-title":"Otolaryngologia polska = Pol. otolaryngology"},{"key":"B130","article-title":"IMFINZI (durvalumab) [Prescribing Information]","author":"Wilmington","year":"2024"},{"key":"B109","doi-asserted-by":"publisher","first-page":"5649","DOI":"10.1200\/JCO.2008.19.1866","article-title":"Bevacizumab reverses cerebral radiation necrosis","volume":"26","author":"Wong","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.2147\/DDDT.S162214","article-title":"Safety and efficacy of durvalumab (MEDI4736) in various solid tumors","volume":"12","author":"Yang","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"B111","doi-asserted-by":"publisher","first-page":"101202","DOI":"10.1016\/j.ajoc.2021.101202","article-title":"Audiology findings in patients with teprotumumab associated otologic symptoms","volume":"24","author":"Yu","year":"2021","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"B112","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1080\/14740338.2024.2328321","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system events for daratumumab","volume":"23","author":"Yun","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"B113","article-title":"Teprotumumab. Update 2023 Sep 4","volume-title":"StatPearls","author":"Yvon","year":"2025"},{"key":"B114","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell. and Mol. Immunol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s11096-023-01676-9","article-title":"Data mining and analysis of adverse event signals associated with teprotumumab using the Food and Drug Administration adverse event reporting system database","volume":"46","author":"Zhang","year":"2024","journal-title":"Int. J. Clin. Pharm."},{"key":"B116","doi-asserted-by":"publisher","first-page":"1393940","DOI":"10.3389\/fphar.2024.1393940","article-title":"Adverse event reporting of the IGF-1R monoclonal antibody teprotumumab: a real-world study based on the US food and drug administration adverse event reporting system","volume":"15","author":"Zhao","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"B118","doi-asserted-by":"publisher","first-page":"e36010","DOI":"10.1097\/MD.0000000000036010","article-title":"Sensorineural hearing loss induced by gefitinib: a CARE-compliant case report and literature reviews","volume":"102","author":"Zhu","year":"2023","journal-title":"Medicine"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1620679\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T05:45:45Z","timestamp":1758087945000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1620679\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":130,"alternative-id":["10.3389\/fphar.2025.1620679"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1620679","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,17]]},"article-number":"1620679"}}